Your browser doesn't support javascript.
loading
Chemotherapy is not needed when complete evacuation of gestational choriocarcinoma leads to hCG normalization.
Bolze, Pa; Schoenen, S; Margaillan, M; Braga, A; Sauthier, P; Elias, K; Seckl, M; Winter, M; Coulter, J; Lok, C; Joneborg, U; Undurraga Malinverno, M; Hajri, T; Massardier, J; You, B; Golfier, F; Goffin, F.
Afiliação
  • Bolze P; Centre Français de Référence des Maladies Trophoblastiques, CHU Lyon Sud, France. Electronic address: pierre-adrien.bolze@chu-lyon.fr.
  • Schoenen S; Centre Belge de Référence des Maladies Trophoblastiques, Liège, Belgium. Electronic address: s.schoenen@chuliege.be.
  • Margaillan M; Centre Français de Référence des Maladies Trophoblastiques, CHU Lyon Sud, France.
  • Braga A; Rio de Janeiro Trophoblastic Disease Reference Center, Rio de Janeiro, Brazil.
  • Sauthier P; Réseau des Maladies Trophoblastiques Du Québec, Montréal, Canada.
  • Elias K; New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, USA.
  • Seckl M; Charing Cross Gestational Trophoblastic Disease Center, London, UK.
  • Winter M; Sheffield Center for Trophoblastic Diseases, Sheffield, UK.
  • Coulter J; Department of Gynaecology Obstetrics, Cork University Maternity Hospital, Cork, Ireland.
  • Lok C; Center of Gynaecologic Oncology, Amsterdam, Netherlands.
  • Joneborg U; Department of Women's and Children's Health and Department of Pelvic Cancer, Karolinska Institutet/University Hospital, Stockholm, Sweden.
  • Undurraga Malinverno M; Unité D'oncogynécologie, Département de Gynécologie et Obstétrique, Hôpitaux Universitaires de Genève, Genève, Switzerland.
  • Hajri T; Centre Français de Référence des Maladies Trophoblastiques, CHU Lyon Sud, France.
  • Massardier J; Centre Français de Référence des Maladies Trophoblastiques, CHU Lyon Sud, France.
  • You B; Centre Français de Référence des Maladies Trophoblastiques, CHU Lyon Sud, France.
  • Golfier F; Centre Français de Référence des Maladies Trophoblastiques, CHU Lyon Sud, France.
  • Goffin F; Centre Belge de Référence des Maladies Trophoblastiques, Liège, Belgium.
Eur J Surg Oncol ; 50(3): 108012, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38350264
ABSTRACT

BACKGROUND:

The standard treatment for gestational choriocarcinoma is chemotherapy.

OBJECTIVE:

To describe the risk of recurrence with expectant management of gestational choriocarcinoma that has reached a normal human chorionic gonadotropin level after tumor removal without adjuvant chemotherapy.

METHODS:

A retrospective multicenter international cohort study was conducted from 1981 to 2017 involving 11 gestational trophoblastic disease reference centers with patient's follow-up extended until 2023. Clinical and biological data of included patients were extracted from each center's database. The inclusion criteria were i) histological diagnosis of gestational choriocarcinoma in any kind of placental tissue retrieved, ii) spontaneous normalization of human chorionic gonadotropin level following choriocarcinoma retrieval, iii) patient did not receive any oncological treatment for the choriocarcinoma, iv) and at least 6 months of follow-up after the first human chorionic gonadotropin level normalization.

RESULTS:

Among 80 patients with retrieved gestational choriocarcinoma and whose human chorionic gonadotropin level normalized without any other oncological therapy, none had a recurrence of choriocarcinoma after a median follow-up of 50 months. The median interval between choriocarcinoma excision and human chorionic gonadotropin level normalization was 48 days. The International Federation of Gynecology and Obstetrics/World Health Organization risk score was ≤6 in 93.7% of the cases.

CONCLUSIONS:

This multicenter international study reports that selected patients with gestational choriocarcinoma managed in gestational trophoblastic disease reference centers did not experience any relapse when the initial tumor evacuation is followed by human chorionic gonadotropin level normalization without any additional treatment. Expectant management may be a safe approach for highly selected patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Uterinas / Coriocarcinoma / Doença Trofoblástica Gestacional Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Female / Humans / Pregnancy Idioma: En Revista: Eur J Surg Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Uterinas / Coriocarcinoma / Doença Trofoblástica Gestacional Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Female / Humans / Pregnancy Idioma: En Revista: Eur J Surg Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article